Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma

Vogel, Arndt; Saborowski, Anna

doi:10.1016/j.ctrv.2019.101946

Cited by 109 publications

(137 citation statements)

References 50 publications

Supporting

Mentioning

128

Contrasting

Order By: Relevance

“…Surgical resection, liver transplantation, and locoregional therapies are potential curative treatment options for early or intermediate stage HCC (Kirstein and Wirth, 2020). For patients with advanced HCC, however, only two targeted drugs-multi-kinase inhibitor sorafenib, and the vascular endothelial growth factor-2 (VEGFR-2) antagonist ramucirumabthat only increase patient survival by few months exist (Lurje et al, 2019;Vogel and Saborowski, 2020). Therefore, the development of alternative methods of treatment needs urgent attention.…”

Section: Introductionmentioning

confidence: 99%

Anti-Cancer Effects of Lycopene in Animal Models of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

Introduction: Globally, hepatocellular carcinoma (HCC) is the sixth most diagnosed cancer and the third important cause of cancer-related death. As there are only two targeted drugs for the treatment of advanced HCC-that merely extend survival by a few months-the need for alternative treatments is inevitable. Lycopene, a carotenoid that is known to be most abundant in red tomatoes and tomato-based products, has been investigated for its anticancer activity in various types of cancers including HCC. This review was conducted to evaluate the effects of lycopene on HCC from animal models to pave the way for further clinical studies. Methods: Electronic databases and search engines including PubMed, EMBASE, and Google Scholar were searched for original records addressing the anticancer effect of lycopene in animal models of HCC. Data were extracted using a format prepared in Microsoft Excel and exported to Stata 15.0 for analyses. A meta-analysis was performed using a random-effects model at a 95% confidence level for the outcome measures: tumor incidence, number, and growth (tumor volume and size). The presence of publication bias between studies was evaluated using Egger's test and funnel plot. The study protocol was registered in the PROSPERO database with reference number: CRD42019159312. Results: The initial database search yields 286 articles, of which 15 studies met the inclusion criteria. The characteristics of the included studies were a bit diversified. The studies involved a total of 644 animals (312 treatment and 332 control groups) and mice shared the majority (488) followed by rats (117) and ferrets (39). The meta-analysis showed that lycopene significantly reduced the incidence [RR 0.8; 95% CI 0.69, 0.92 (p=0.00); I 2 = 30.4%, p=0.16; n=11], number [SMD-1.83; 95% CI-3.10,-0.57 (p=0.01); I 2 = 95.9%, p=0.00; n=9], and growth [SMD-2.13; 95% CI-4.20,-0.04 (p=0.04); I 2 = 94.6%, p=0.00; n=4] of HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Anti-Cancer Effects of Lycopene in Animal Models of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Although the clinical diagnosis and treatment of early HCC have improved significantly, the prognosis of HCC is still very poor [2,3]. In addition, highly invasive and advanced HCC responds minimally or not at all to general treatment [4][5][6]. Therefore, there is an urgent need for new valid and well-tolerated treatment strategies.…”

Section: Introductionmentioning

confidence: 99%

Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of Hepatocellular Carcinoma

Hu¹,

Chen²,

Zhang³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Objective: To explore the effect of COX-2 inhibitor celecoxib in combination with metformin on the prevention of Hepatocellular carcinoma (HCC) and the mechanisms involved. Methods: HCC cell lines and an HCC rat model were treated with celecoxib, metformin or a combination of both. Cell viability and tumor formation were measured. Results: In vitro and in vivo studies showed that treatment with a combination of celecoxib and metformin inhibited proliferation of HCC to a greater extent than either treatment alone, by reducing the phosphorylation of MTOR. Conclusion: The study suggested that celecoxib combined with metformin would be more effective for the preventing occurrence of HCC than either treatment alone and this combination of therapy is worthy of further study.

show abstract

“…Factors of early or late recurrence or/and metastases were complex, including tumor size and history of rupture, etc. (11,14,15).…”

Section: Introductionmentioning

confidence: 99%

Surveillance Strategy for Patients With BCLC Stage B Hepatocellular Carcinoma After Achieving Complete Remission: Data From the Real World

Shen

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Purpose: There is a lack of consensus on the surveillance strategy for Barcelona Clinic liver cancer (BCLC) stage B hepatocellular carcinoma (HCC) patients with complete remission (CR). We performed a real-world, retrospective analysis of the surveillance strategy for BCLC stage B HCC patients after radical therapy with CR to support clinical decision-making. Materials and Methods: We analyzed 546 BCLC stage B HCC patients with CR after radical treatments (surgery/ablation) at Sun Yat-sen University Cancer Center, from January 2007 to December 2019. The intensity of surveillance interval was defined as the mean of surveillance interval within 2 years. The primary endpoint of the study was overall survival (OS) and extra-Milan criteria relapse. Results: During a median follow-up time of 23.9 months (range = 3.1-148.3 months), there were 11.9% of patients died, 56.6% of patients developed recurrence, the vast majority of patients experienced recurrence within 2 years, and 27.8% patients developed extra-Milan criteria recurrence. The median disease-free survival and OS were 33.6 and 60.0 months, respectively. Patients were divided into regular surveillance group (RS) (≤4.3 months) and irregular surveillance (IRS) group (>4.3 months) based on the optimal cutoff value of the intensity of surveillance interval. The RS group owned a lower incident of extra-Milan criteria relapse and smaller and fewer tumors at recurrence than IRS group, which contributed to the prolonged OS. Besides, the cutoff values of surveillance interval that could lead to significant differences in the incidence of extra-Milan criteria relapse during 0-6, 6-12, and 12-18 months after CR were 2.6, 2.9, and 3 months, respectively. Conclusions: The average surveillance interval for patients with BCLC stage B HCC achieved CR should not exceed 4.3 months during the first 2 years' follow-up. During three different phases of the initial 18 months after CR, individualized surveillance showed intervals no more than 3 months were required to reduce the incidence of extra-Milan criteria relapse.

show abstract

Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma

Cited by 109 publications

References 50 publications

Anti-Cancer Effects of Lycopene in Animal Models of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Anti-Cancer Effects of Lycopene in Animal Models of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of Hepatocellular Carcinoma

Surveillance Strategy for Patients With BCLC Stage B Hepatocellular Carcinoma After Achieving Complete Remission: Data From the Real World

Contact Info

Product

Resources

About